The financial cost of managing primary open angle glaucoma by trabeculectomy at diagnosis was compared with the cost of a more conventional sequence of medical therapy followed by trabeculectomy only in unsuccessful cases. Costs were estimated at 1989 prices for 104 patients studied in a prospective randomised multicentre trial which had been running for eight years. Separate estimates were made for operative costs, inpatient costs, and outpatient costs including visual field tests and medi cations. Values were adjusted to allow for the observed mortality rate within the group.
cost within the first year, in subsequent years the conventionally managed group was consistently more expensive and so overall costs were similar. Inpatient care was the most expensive item in both groups (62% of total cost in conventional management, and 77% with early surgery).
Our current practice is to admit patients for a shorter period than the average of 7.6 days at the time of this trial. We have therefore produced cost estimates based on a shorter inpatient stay of one and four days per operation, and in both cases early surgery becomes the less expensive strategy.
The results have been presented in a form that allows substitution of regional and temporal variations in costs and medical practice.
There is little information about the cost of eye care in Britain. Cost analyses of kera toplasty! and ocular trauma2 have been under taken, but no published information exists for glaucoma care. In the USA the importance of cost efficiency in glaucoma care has been stressed,3,4 but no detailed analysis has been published. For France, Wolmark estimated the national cost of therapy for, and disability produced by, glaucoma, 5 but his data were derived from national statistics with no indica tion of cost per patient.
A recently published clinical trial has demonstrated the benefit of early trabeculec tomy in the managment of open angle glau coma.6,7 However, concern has been expressed about the financial implications of adopting an early surgery policy. This study establishes the difference in costs between a conventional and an early surgery policy, as follow-up. Therefore, 104 were available for this analysis. These patients were assigned to two further groups according to whether one or both eyes fulfilled the entry criteria out lined above. Thus the 104 patients were div ided into four groups of approximately equal size (Table I) . The major categories of National Health Service expenditure were identified and a cost was calculated for each (Table II) . The cost of inpatient care and an outpatient attenda � ce were obtained from Scottish Health ServIce statistics8 and informal enquiry into patient costs at English Eye hospitals suggested similar values. Visual field costs were esti mated on time required for manual bowl per imetry or Friedmann field analysis in glaucoma patients. These instruments we � e almost exclusively used for field assessment III the trial. Drug costs9 were calculated assum ing full patient compliance and the use of one including operation was the responsibility of Patients the referring ophthalmologist. There were 120 116 patients in the trial but four refused early surgery, the case records of two patients were untraceable, and six patients had been lost to bottle of each topical medication per month per patient. The drug cost included a pharma cists' Health Service prescription fee which added 6% to the total drug bill, 1989 prices were used and no adjustment was made for inflation. Expenses for cataract surgery or non-ophthalmic complications of therapy have not been included in the total costs, but the rate of cataract formation or extraction was the same in groups A and B. 6 For each year of follow up the mean costs per patient per year for inpatient days, oper ations, outpatient attendances, field tests and drugs were obtained by review of the case records. An adjustment for mortality was applied to these costs using survival data for the trial patients over the eight years of the study (Fig. 1 ). For example, the cost per patient in year five was reduced by 12% as 12% of the patients in the trial had died by the beginning of their fifth year in the trial. In this manner a prospective cost per patient for a glaucoma population was derived and this adjusted cost was used rather than an average cost per survivor. Data were entered on an Amstrad PCl640 microcomputer running a Framework (Ash ton-Tate) spreadsheet, and mean costs per patient year for outpatient and inpatient care were calculated.
The effect of reduced inpatient stay on cost was investigated by modification of existing data as if there had been either an average one day (24 hours) admission or four day admission. The resulting cost estimates were compared with those seen in the trial patients.
Results Table III shows the mean number of inpatient days, outpatient attendances, theatre visits, drug items and field tests per patient for each year following diagnosis. Table IV presents the mean costs per patient for the same items over the eight year period following diag nosis. It can be seen that the mean costs in the bilateral group were higher than those of patients presenting with only one eye that ful filled the trial entry criteria. However, the mean cost of care for bilateral cases was less than twice that of the unilateral cases, partly because some patients in the unilateral group later required treatment in the fellow eye.
Both incurred the greatest expense during the first year, and the mean expenditure in group B in this first year was approximately twice that of the conventional group A. However, group A engendered the greater cost for each of the succeeding seven years of follow-up. In the bilateral group, the total cost per patient over an eight year period (Table IV) was almost identical for group A (£2, 568. 62: conventional management) and B (£2, 560.48: early surgery). Patients presenting with uni lateral disease showed a slightly lower cost when managed conventionally: £1, 920. 22 compared with £2, 138. 99 for early surgery. Figure 2 compares the timing of expendi ture for the bilateral cases in groups A and B. Figure 3 illustrates the distribution of expenditure in the bilateral cases of groups A and B. It can be seen that group A incurred increased inpatient costs compared with group B as more operations were performed. However, more expenditure was required for drugs, outpatient attendance and field testing in group B which compensated for the dispar ity in inpatient costs.
Costs were reassessed for shorter periods of 
Year
Total eoet mated that a one-day admission for surgery 1 would incur £95 theatre costs, £125 ward I costs, and £100 costs for additional outpatient attendances with transport. A four day admission was estimated to produce £95 the atre costs, and £500 ward costs. For the one day admission cost reductions of 45% for the conventional group A and 56% for the early surgery group B were predicted. For a four day admission group A costs decreased by 27% and group B by 30% (Figure 4 ).
Discussion
We have presented the pattern of expenditure encountered over the eight-year period fol lowing diagnosis of open angle glaucoma. Values obtained from hospitals within the Strathclyde region8 (Table II) have been used to calculate costs of in-and out-patient care, but many hospitals will soon have locally derived data,1O and so we have presented the required information to allow substitution of alternative cost assumptions (Table III) .
Only the direct aspects of glaucoma care Table III and IV. It was esti- and its ophthalmic complications were con sidered. No account was made to cost disabil ity from the disease and a cost-benefit analysis was not attempted. It has, however, been shown that there is a significant benefit for the early surgery group in preservation of visual field. 6,7 In this study Argon laser trabeculo plasty was used twice and automated perime try was performed very infrequently. Therefore no attempt was made to include extra costs for these items. They may be expensive optionsll and would require inclusion in cost analyses for units where such techniques comprise a large component of glaucoma management. The calculation of costs adjusted for mor tality favoured the conventional management group. In the early surgery group nearly all the inpatient costs occurred in the first year and so were little reduced by allowance for mortality. By comparison, in the conventional management group inpatient, and indeed all costs, spread into later years and therefore underwent a greater reduction by mortality adjustment. Eliminating the effects of infla tion will also have favoured the conventional group for similar reasons.
It might be argued that the cost assump tions used in this study were not sufficiently comprehensive. For instance, no consider ation has been given to patient transport costs, general practitioner duties, or patient compliance. These would be difficult to quan tify and would probably have contributed little to overall costs. Perhaps the greatest uncertainty derives from the use of Health Service statistics,8 notably those relating to inpatient care. With the introduction of diag nosis-related group (DRG) statistics/a more reliable estimates should be obtainable soon.
Using keratoplasty data from a previous cost analysis by Menage et at. 1 we have been able to compare the costs of glaucoma surgery and keratoplasty. They presented data for three years of follow-up and therefore we have restricted costs of glaucoma treatment to the same period. Identical cost assumptions (Table II) were substituted for both groups of patients and the resulting comparison is shown in Figure 5 . At £2, 210 over 3 years bilateral glaucoma surgery is less expensive than unilateral keratoplasty, which was esti mated to cost £3, 750.
Concern has been expressed that a wide spread change towards a policy of early trabe culectomy would result in a substantial increase in expenditure on glaucoma care. We have now demonstrated that there is no cost increase for a patient with bilateral glaucoma, and that the costs of a patient who presents with unilateral glaucoma would be only mar ginally increased if early surgery were per formed. Many of the fellow eyes in the unilateral group of patients went on to develop ocular hypertension or glaucoma at a variable interval following entry into the trial, and it was not possible to separate the costs of review and therapy for each eye with any accuracy. Therefore we have devoted most of our analysis to the data from the more homog eneous bilateral group.
Pounds(£)
The minimal difference in total expenditure between groups A and B masks a marked alteration in the composition of this total sum (Fig. 3) . With early trabeculectomy there is a reduced requirement for all aspects of out patient care, balanced by a 30% increase in inpatient costs. The greatest change is seen in pharmaceutical expenditure, which IS reduced by over 60% .
The few days spent as an inpatient pro duced greater than 50% of the total expendi ture. The medical staff responsible for the care of the patients in the study were surprised to learn that the average inpatient stay was as long as 7.6 days per operation. However, the average inpatient stay per operation in those randomised to bilateral early surgery was only 6.8 days, as a majority of the patients under went surgery to both eyes during the same admission. Minor postoperative problems such as a small hyphaema or mild shallowing of the anterior chamber were the commonest causes of admissions of greater than one week. With the improved surgical technique and more confident postoperative care that is appearing with greater use of trabeculectomy, patients are now in hospital for a shorter period. Figure 5 illustrates the hypothetical costs of a patient staying in hospital one night or four nights per operation. It can be seen that a considerable saving is engendered in both groups A and B, and that the early sur gery option becomes more cost efficient than a conventional approach when a shorter hospital stay is adopted. An emphasis on admission length in cost efficiency has been criticised in general surgery as the costs of pre operative assessment and the operation itself can be considerable.12 The same argument does not apply to most elective ophthalmic operations which require relatively little pre operative assessment and theatre time. It is our current practice to admit patients for about four days per operation, and a one day admission is theoretically possible. These shorter admissions produce a cost advantage for an early operation strategy, and if they can be generally employed without increased postoperative complications will significantly reduce the overall cost of glaucoma care.
